DOCSLIB.ORG

Mechanism of SOS Mutagenesis of UV-Irradiated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mechanism of SOS Mutagenesis of UV-Irradiated Proc. Natl. Acad. Sci. USA Vol. 89, pp. 1159-1163, February 1992 Genetics Mechanism of SOS mutagenesis of UV-irradiated DNA: Mostly error-free processing of deaminated cytosine (A-rule/umusDC/groE/pyrimidine dimers/phages S13 and A) IRWIN TESSMAN, SHI-KAU Liu, AND MATTHEW A. KENNEDY Department of Biological Sciences, Purdue University, West Lafayette, IN 47907 Communicated by R. B. Setlow, November 8, 1991 (receivedfor review July 16, 1991) ABSTRACT We measured the kinetics of growth and correctly during bypass of the dimers, adenines would be mutagenesis of UV-irradiated DNA of phages S13 and A that found in the newly synthesized complementary strand. If were undergoing SOS repair; the kinetics strongly suggest that there is adequate time for deamination to occur, and that is most of SOS mutagenesis arises from the deamination of the very central issue here, bypass of lesions will usually cytosine in cyclobutane pyrimidine dimers, producing C -3 T involve the insertion of the sequence A-A opposite cyclob- transitions. This occurs because the SOS mechanism bypasses utane dimers, even opposite those dimers that had originally T'T dimers promptly, while bypass of cytosine-containing contained C. Because of the distorted template, partially dimers is delayed long enough for deamination to occur. The relaxed proofreading might be needed to facilitate the accu- mutations are thus primarily the product of a faithful mech- rate bypass (6, 7). anism of lesion bypass by a DNA polymerase and are not, as The foundation for the current work lies in our study of had been generally thought, the product of an error-prone mutagenesis by delayed photoreactivation of UV-irradiated mechanism. All of these observations are explained by the phage S13 and its naked DNA (8). In that work we attributed A-rule, which is that adenine nucleotides are inserted nonin- all of the mutagenesis to the deamination of cytosine, which structionally opposite DNA lesions. occurs readily when the 5,6 bond of the base is saturated (9, 10), as it is in cyclobutane dimers. We proposed, therefore, SOS repair and SOS mutagenesis were discovered nearly 40 that most SOS mutagenesis of UV-irradiated DNA might Jean result from error-free translesion DNA synthesis after deam- years ago by Weigle, who observed that preirradiation ination occurs. The kinetics ofthe mutagenic effect produced of the bacterial host increased survival of UV-irradiated by delayed photoreactivation is an unusual step function: phage A (1). When applied to phage DNA these SOS phe- storage of UV-irradiated phage for 15 min at 37°C is not nomena are now called Weigle reactivation and Weigle mutagenic, indicating that deamination is negligible in that mutagenesis; their mechanism has thus been an intriguing time, but an additional 15 min of storage is highly mutagenic, puzzle for some time. We show here that the primary, but not suggesting that deamination of practically all available sites the sole, mechanism of UV mutagenesis in phages S13 and A occurs by 30 min (8). More detailed experiments with infec- is simply the spontaneous deamination of cytosine in cyclo- tious S13 DNA show that the transition from negligible to butane pyrimidine dimers. This deamination occurs during a nearly complete mutagenesis occurs between 25 and 30 min deliberate, and arguably an unnecessary, delay in the bypass ofDNA storage at 37°C (unpublished data). Earlier studies of of the lesion by DNA polymerase; the delay is caused by mutagenesis by delayed photoreactivation had already indi- cytosine-containing dimers, possibly because of the mispair- cated that dimerized cytosines in the double-stranded DNA ing of the cytosine with adenine. of E. coli are deaminated in vivo within 90 min at 37°C (11). SOS repair is induced by damage to DNA. In Escherichia We predicted that if a sufficiently long delay were an intrinsic coli, the damage results in an activated form of the RecA aspect of the SOS repair process, deamination of the cy- protein, which can mediate the cleavage of LexA, the re- tosines in UV-induced dimers could have time to occur and pressor ofthe SOS regulon. The principal known components would then be a source of the C -+ T mutations that are so of the repair system are the products of the recA and the commonly induced by UV irradiation. We show here that umuDC genes. The activated RecA protein is needed for Weigle mutagenesis is indeed characterized by a delay in cleavage of the UmuD protein to produce UmuD', the active repair that is on the order of the time needed for deamination C-terminal fragment (2-4). The RecA protein can also be of dimerized cytosines. activated by mutations designated recA(Prtc) to what is Weigle reactivation of phage S13 occurs effectively in a termed the protease constitutive state (5); with mutants such groE mutant, but 80% of the mutagenesis is eliminated (7). as recAl202(Prtc) and recAJ237(Prtc), which were used in the We will describe here a recA mutant that accomplishes work described here, Weigle reactivation is achieved without essentially the same thing, namely, efficient reactivation of irradiation of the host cell. S13, and of phage A too, but with severely reduced muta- It is generally thought that a high frequency of erroneous genesis. Thus, mutagenesis is not an essential aspect of SOS base pairing during DNA synthesis opposite the distorted repair. We will explain the effect of these novel mutants by lesion is responsible for the mutagenesis that accompanies showing that they are characterized by reactivation of UV SOS repair, and that idea has evoked the term error-prone lesions in a time too short for deamination to occur. repair. We propose, instead, that most, though certainly not One of us has proposed a theory of the mechanism of all, ofthe mutations arise through accurate base pairing-i.e., Weigle reactivation (12) that is sometimes called the A-rule. an error-free bypass mechanism. This paradox will be re- It was proposed in order to explain the specificity of SOS solved by the fact that mutations can arise by deamination of mutagenesis of UV-irradiated DNA, which was first demon- cytosine in cyclobutane dimers; ifthe uracils formed are read strated in phage S13 (13); since the TT dimer is expected to be the major dimer formed, it is notable that the major The publication costs of this article were defrayed in part by page charge mutational change is nevertheless C -* T. That striking result payment. This article must therefore be hereby marked "advertisement" could be explained if the SOS system blindly inserts adenine in accordance with 18 U.S.C. §1734 solely to indicate this fact. nucleotides opposite pyrimidine dimers regardless ofthe base 1159 Downloaded by guest on September 28, 2021 1160 Genetics: Tessman et al. Proc. Natl. Acad. Sci. USA 89 (1992) composition of the dimers, a process that would ensure RESULTS proper pairing for most of the dimerized sites. A similar A-rule has been proposed to explain the successful bypass of The experimental approach was simple. The latent period apurinic/apyrimidinic sites in DNA (14, 15). We will see that between infection and phage burst indicated the time delay associated with the of a lesion. We will see that the A-rule not only explains the C -- T specificity of SOS bypass mutagenesis, but that it also provides a tidy explanation for unirradiated phage S13 has a latent period of 15-20 min. Of the critical delay in the dimer bypass that is a key to the C this, <2 min is needed to synthesize the complement of the T mutations. infecting DNA molecule (20). In the case of UV-damaged DNA we make the reasonable assumption that once the lesion is bypassed and the complement completely synthe- MATERIALS AND METHODS sized, the phage will require no more than an additional 15-20 Strains and Medium. The bacterial strains used in this min to produce a burst. Therefore, ifL is the measured latent study were isogenic derivatives of the E. coli K-12 strain period ofreactivated phage, then L - 20 is the minimum time AB1157. All strains contained the sulAIl dinDl::Mu d(lac) needed for the bypass of the lesion. If this delay time is >30 alleles. The two high-copy-number plasmids pSE117 min, then deamination ofcytosines containing a saturated 5,6 (umuD+C+) and pGW2123 (umuD) were provided by G. C. bond should occur. Walker (4, 16). The original groES30 strain was obtained We first measured the latent period of unirradiated S13 in from C. P. Georgopolous (University of Utah). The chromo- some of the strains of bacteria that were used for Weigle somal recAl202 and recAl237 strains were constructed by reactivation and found (Table 1, lines 1-3) that the latent crossing the ArecA1202 and ArecA1237 phages with a recA' period was between 15 and 20 min, in agreement with A(gal-attA-bio) strain. All ArecA lysogens contained the previous data (22). The latent period of irradiated phage chromosomal ArecA306 allele (5); the ArecAl237 strains reactivated in strain IT1993, which contains constitutively also activated RecA, was between 115 and 130 min (line 4). We IT3663 and IT3665 contained the IexA(Def)71::TnS al- infer that the delay before the initial bypass occurred was lele. Tryptone broth contained 13 g of Bacto-tryptone and 7 between 95 and 110 min, which should allow adequate time g of NaCl per liter. for dimerized cytosines to be deaminated and thereby be a Determination of Latent Periods for Phages S13 and A. To major source of Weigle mutagenesis. The degree of muta- measure replication delay, bacterial cells were grown in genesis is quantitatively represented in Table 1 by the specific tryptone broth (with 0.2% maltose in the A experiments) to mutation frequency, Ms, which is defined as the number of =4 x 108 per ml.
Load more

Recommended publications
  • Chapter 14: Functional Genomics Learning Objectives
    Chapter 14: Functional Genomics Learning objectives Upon reading this chapter, you should be able to: ■ define functional genomics; ■ describe the key features of eight model organisms; ■ explain techniques of forward and reverse genetics; ■ discuss the relation between the central dogma and functional genomics; and ■ describe proteomics-based approaches to functional genomics. Outline : Functional genomics Introduction Relation between genotype and phenotype Eight model organisms E. coli; yeast; Arabidopsis; C. elegans; Drosophila; zebrafish; mouse; human Functional genomics using reverse and forward genetics Reverse genetics: mouse knockouts; yeast; gene trapping; insertional mutatgenesis; gene silencing Forward genetics: chemical mutagenesis Functional genomics and the central dogma Approaches to function; Functional genomics and DNA; …and RNA; …and protein Proteomic approaches to functional genomics CASP; protein-protein interactions; protein networks Perspective Albert Blakeslee (1874–1954) studied the effect of altered chromosome numbers on the phenotype of the jimson-weed Datura stramonium, a flowering plant. Introduction: Functional genomics Functional genomics is the genome-wide study of the function of DNA (including both genes and non-genic regions), as well as RNA and proteins encoded by DNA. The term “functional genomics” may apply to • the genome, transcriptome, or proteome • the use of high-throughput screens • the perturbation of gene function • the complex relationship of genotype and phenotype Functional genomics approaches to high throughput analyses Relationship between genotype and phenotype The genotype of an individual consists of the DNA that comprises the organism. The phenotype is the outward manifestation in terms of properties such as size, shape, movement, and physiology. We can consider the phenotype of a cell (e.g., a precursor cell may develop into a brain cell or liver cell) or the phenotype of an organism (e.g., a person may have a disease phenotype such as sickle‐cell anemia).
    [Show full text]
  • Mutational Signatures: Emerging Concepts, Caveats and Clinical Applications
    REVIEWS Mutational signatures: emerging concepts, caveats and clinical applications Gene Koh 1,2, Andrea Degasperi 1,2, Xueqing Zou1,2, Sophie Momen1,2 and Serena Nik-Zainal 1,2 ✉ Abstract | Whole-genome sequencing has brought the cancer genomics community into new territory. Thanks to the sheer power provided by the thousands of mutations present in each patient’s cancer, we have been able to discern generic patterns of mutations, termed ‘mutational signatures’, that arise during tumorigenesis. These mutational signatures provide new insights into the causes of individual cancers, revealing both endogenous and exogenous factors that have influenced cancer development. This Review brings readers up to date in a field that is expanding in computational, experimental and clinical directions. We focus on recent conceptual advances, underscoring some of the caveats associated with using the mutational signature frameworks and highlighting the latest experimental insights. We conclude by bringing attention to areas that are likely to see advancements in clinical applications. The concept of mutational signatures was introduced or drug therapies, in an attempt to decipher causes7–9. in 2012 following the demonstration that analy­ However, the origins of many signatures remain cryp­ sis of all substitution mutations in a set of 21 whole­ tic. Furthermore, while earlier analyses reported single genome­sequenced (WGS) breast cancers could reveal signatures, for example of UV radiation (that is, SBS7)2, consistent patterns of mutagenesis across tumours1 more recent studies reported multiple versions of these (FIG. 1a). These patterns were the physiological imprints signatures (that is, SBS7a, SBS7b, SBS7c and SBS7d)3, of DNA damage and repair processes that had occurred leading the community to question whether some find­ during tumorigenesis and could distinguish BRCA1­null ings are reflective of biology or are simply mathemat­ and BRCA2­null tumours from sporadic breast cancers.
    [Show full text]
  • Gene Therapy Glossary of Terms
    GENE THERAPY GLOSSARY OF TERMS A • Phase 3: A phase of research to describe clinical trials • Allele: one of two or more alternative forms of a gene that that gather more information about a drug’s safety and arise by mutation and are found at the same place on a effectiveness by studying different populations and chromosome. different dosages and by using the drug in combination • Adeno-Associated Virus: A single stranded DNA virus that has with other drugs. These studies typically involve more not been found to cause disease in humans. This type of virus participants.7 is the most frequently used in gene therapy.1 • Phase 4: A phase of research to describe clinical trials • Adenovirus: A member of a family of viruses that can cause occurring after FDA has approved a drug for marketing. infections in the respiratory tract, eye, and gastrointestinal They include post market requirement and commitment tract. studies that are required of or agreed to by the study • Adeno-Associated Virus Vector: Adeno viruses used as sponsor. These trials gather additional information about a vehicles for genes, whose core genetic material has been drug’s safety, efficacy, or optimal use.8 removed and replaced by the FVIII- or FIX-gene • Codon: a sequence of three nucleotides in DNA or RNA • Amino Acids: building block of a protein that gives instructions to add a specific amino acid to an • Antibody: a protein produced by immune cells called B-cells elongating protein in response to a foreign molecule; acts by binding to the • CRISPR: a family of DNA sequences that can be cleaved by molecule and often making it inactive or targeting it for specific enzymes, and therefore serve as a guide to cut out destruction and insert genes.
    [Show full text]
  • The Limitations of DNA Interstrand Cross-Link Repair in Escherichia Coli
    Portland State University PDXScholar Dissertations and Theses Dissertations and Theses 7-12-2018 The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli Jessica Michelle Cole Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the Biology Commons Let us know how access to this document benefits ou.y Recommended Citation Cole, Jessica Michelle, "The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli" (2018). Dissertations and Theses. Paper 4489. https://doi.org/10.15760/etd.6373 This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli by Jessica Michelle Cole A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biology Thesis Committee: Justin Courcelle, Chair Jeffrey Singer Rahul Raghavan Portland State University 2018 i Abstract DNA interstrand cross-links are a form of genomic damage that cause a block to replication and transcription of DNA in cells and cause lethality if unrepaired. Chemical agents that induce cross-links are particularly effective at inactivating rapidly dividing cells and, because of this, have been used to treat hyperproliferative skin disorders such as psoriasis as well as a variety of cancers. However, evidence for the removal of cross- links from DNA as well as resistance to cross-link-based chemotherapy suggests the existence of a cellular repair mechanism.
    [Show full text]
  • Transposon Insertion Mutagenesis in Mice for Modeling Human Cancers: Critical Insights Gained and New Opportunities
    International Journal of Molecular Sciences Review Transposon Insertion Mutagenesis in Mice for Modeling Human Cancers: Critical Insights Gained and New Opportunities Pauline J. Beckmann 1 and David A. Largaespada 1,2,3,4,* 1 Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA; [email protected] 2 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA 3 Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA 4 Center for Genome Engineering, University of Minnesota, Minneapolis, MN 55455, USA * Correspondence: [email protected]; Tel.: +1-612-626-4979; Fax: +1-612-624-3869 Received: 3 January 2020; Accepted: 3 February 2020; Published: 10 February 2020 Abstract: Transposon mutagenesis has been used to model many types of human cancer in mice, leading to the discovery of novel cancer genes and insights into the mechanism of tumorigenesis. For this review, we identified over twenty types of human cancer that have been modeled in the mouse using Sleeping Beauty and piggyBac transposon insertion mutagenesis. We examine several specific biological insights that have been gained and describe opportunities for continued research. Specifically, we review studies with a focus on understanding metastasis, therapy resistance, and tumor cell of origin. Additionally, we propose further uses of transposon-based models to identify rarely mutated driver genes across many cancers, understand additional mechanisms of drug resistance and metastasis, and define personalized therapies for cancer patients with obesity as a comorbidity. Keywords: animal modeling; cancer; transposon screen 1. Transposon Basics Until the mid of 1900’s, DNA was widely considered to be a highly stable, orderly macromolecule neatly organized into chromosomes.
    [Show full text]
  • The Repertoire of Mutational Signatures in Human Cancer
    Article The repertoire of mutational signatures in human cancer https://doi.org/10.1038/s41586-020-1943-3 Ludmil B. Alexandrov1,25, Jaegil Kim2,25, Nicholas J. Haradhvala2,3,25, Mi Ni Huang4,5,25, Alvin Wei Tian Ng4,5, Yang Wu4,5, Arnoud Boot4,5, Kyle R. Covington6,7, Dmitry A. Gordenin8, Received: 18 May 2018 Erik N. Bergstrom1, S. M. Ashiqul Islam1, Nuria Lopez-Bigas9,10,11, Leszek J. Klimczak12, Accepted: 18 November 2019 John R. McPherson4,5, Sandro Morganella13, Radhakrishnan Sabarinathan10,14,15, David A. Wheeler6,16, Ville Mustonen17,18,19, PCAWG Mutational Signatures Working Group20, Published online: 5 February 2020 Gad Getz2,3,21,22,26, Steven G. Rozen4,5,23,26*, Michael R. Stratton13,26* & PCAWG Consortium24 The number of DBSs is proportional to the number of SBSs, with few exceptions Open access Somatic mutations in cancer genomes are caused by multiple mutational processes, each of which generates a characteristic mutational signature1. Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium2 of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), we characterized mutational signatures using 84,729,690 somatic mutations from 4,645 whole-genome and 19,184 exome sequences that encompass most types of cancer. We identifed 49 single-base-substitution, 11 doublet-base-substitution, 4 clustered-base-substitution and 17 small insertion-and-deletion signatures. The substantial size of our dataset, compared with previous analyses3–15, enabled the discovery of new signatures, the separation of overlapping signatures and the decomposition of signatures into components that may represent associated—but distinct—DNA damage, repair and/or replication mechanisms.
    [Show full text]
  • Incision by Uvrabc Excinuclease Is a Step in the Path to Mutagenesis By
    Proc. Nati. Acad. Sci. USA Vol. 86, pp. 3982-3986, June 1989 Biochemistry Incision by UvrABC excinuclease is a step in the path to mutagenesis by psoralen crosslinks in Escherichia coli (plasmid mutagenesis/pSV2-gpt/homologous recombination/angelicin/deletions) FRANCES M. SLADEK*t, AGUSTIN MELIANt, AND PAUL HOWARD-FLANDERS§ Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06511 Communicated by Fred Sherman, February 21, 1989 (receivedfor review June 10, 1988) ABSTRACT 4,5',8-Trimethylpsoralen (psoralen) plus yield of SOS-dependent mutations (15, 16), which tend to be near UV light produces interstrand crosslinks and monoad- base-pair substitutions (17-19). ducts in DNA, both ofwhich are mutagenic. InEscherichia coil, The repair of crosslinks appears to occur by a sequential crosslinks are incised by UvrABC excinuclease, an event that excision-recombination mechanism (20, 21). In vitro studies can lead to homologous recombination and repair. To deter- show that crosslinked DNA is incised by the UvrABC exci- mine whether UvrABC incision of crosslinks is a step in the nuclease (22, 23) so that an 11-base oligonucleotide containing path to mutagenesis as well as repair, the effect of DNA the crosslink is left attached to an intact DNA strand (24). They homologous to a target gene on a plasmid was determined. also show that RecA-mediated strand exchange can proceed pSV2-gpt DNA was treated with psoralen and transformed into past the crosslinked oligonucleotide (25) and that a second a pair of hosts: one was gpt', the other was A(gpt-ac)5. The round of incision by UvrABC can release the psoralen moeity DNA was extracted and transformed into a tester strain from the DNA (25, 26).
    [Show full text]
  • Molecular Biology and Applied Genetics
    MOLECULAR BIOLOGY AND APPLIED GENETICS FOR Medical Laboratory Technology Students Upgraded Lecture Note Series Mohammed Awole Adem Jimma University MOLECULAR BIOLOGY AND APPLIED GENETICS For Medical Laboratory Technician Students Lecture Note Series Mohammed Awole Adem Upgraded - 2006 In collaboration with The Carter Center (EPHTI) and The Federal Democratic Republic of Ethiopia Ministry of Education and Ministry of Health Jimma University PREFACE The problem faced today in the learning and teaching of Applied Genetics and Molecular Biology for laboratory technologists in universities, colleges andhealth institutions primarily from the unavailability of textbooks that focus on the needs of Ethiopian students. This lecture note has been prepared with the primary aim of alleviating the problems encountered in the teaching of Medical Applied Genetics and Molecular Biology course and in minimizing discrepancies prevailing among the different teaching and training health institutions. It can also be used in teaching any introductory course on medical Applied Genetics and Molecular Biology and as a reference material. This lecture note is specifically designed for medical laboratory technologists, and includes only those areas of molecular cell biology and Applied Genetics relevant to degree-level understanding of modern laboratory technology. Since genetics is prerequisite course to molecular biology, the lecture note starts with Genetics i followed by Molecular Biology. It provides students with molecular background to enable them to understand and critically analyze recent advances in laboratory sciences. Finally, it contains a glossary, which summarizes important terminologies used in the text. Each chapter begins by specific learning objectives and at the end of each chapter review questions are also included.
    [Show full text]
  • Statement by the Group of Chief Scientific Advisors
    Statement by the Group of Chief Scientific Advisors A Scientific Perspective on the Regulatory Status of Products Derived from Gene Editing and the Implications for the GMO Directive On 25 July 2018, the Court of Justice of the European Biotechnology’ (SAM, 2017a), we have examined the Union ('the Court') decided that organisms obtained GMO Directive taking into account current by the new techniques of directed mutagenesis are knowledge and scientific evidence. genetically modified organisms (GMOs), within the meaning of the Directive 2001/18/EC on the release 1. The Ruling of the Court of Justice of genetically modified organisms into the On request by the French Conseil d'État, the Court environment ('GMO Directive')1,2, and that they are was asked to determine whether organisms subject to the obligations laid down by the GMO obtained by mutagenesis4 should be considered Directive. GMOs and which of those organisms are exempt New techniques of directed mutagenesis include according to the provisions of the GMO Directive. In gene editing such as CRISPR/Cas9 methodologies. particular, the Court was asked to determine The legal status of the products of such techniques whether organisms obtained by new directed was uncertain, because it was unclear whether they mutagenesis techniques are exempt from the fell within the scope of the GMO Directive. obligations imposed by the GMO Directive, as are those obtained by conventional, random These techniques enable the development of a wide mutagenesis techniques that existed before the range of agricultural applications and the ethical, adoption of the Directive, or are regulated like those legal, social and economic issues of their use are obtained by established techniques of genetic discussed intensively.
    [Show full text]
  • Harnessing the Power of Mutagenesis and Adaptive Laboratory Evolution for High Lipid Production by Oleaginous Microalgae and Yeasts
    sustainability Review Harnessing the Power of Mutagenesis and Adaptive Laboratory Evolution for High Lipid Production by Oleaginous Microalgae and Yeasts Neha Arora 1, Hong-Wei Yen 2 and George P. Philippidis 1,* 1 Patel College of Global Sustainability, University of South Florida, 4202 E. Fowler Avenue, Tampa, FL 33620, USA; [email protected] 2 Department of Chemical and Materials Engineering, Tunghai University, Taichung City 407302, Taiwan; [email protected] * Correspondence: [email protected] Received: 8 April 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: Oleaginous microalgae and yeasts represent promising candidates for large-scale production of lipids, which can be utilized for production of drop-in biofuels, nutraceuticals, pigments, and cosmetics. However, low lipid productivity and costly downstream processing continue to hamper the commercial deployment of oleaginous microorganisms. Strain improvement can play an essential role in the development of such industrial microorganisms by increasing lipid production and hence reducing production costs. The main means of strain improvement are random mutagenesis, adaptive laboratory evolution (ALE), and rational genetic engineering. Among these, random mutagenesis and ALE are straight forward, low-cost, and do not require thorough knowledge of the microorganism’s genetic composition. This paper reviews available mutagenesis and ALE techniques and screening methods to effectively select for oleaginous microalgae and yeasts with enhanced lipid yield and understand the alterations caused to metabolic pathways, which could subsequently serve as the basis for further targeted genetic engineering. Keywords: oleaginous; microalgae; yeast; lipid; mutagenesis; adaptive laboratory evolution 1. Introduction Microorganisms with the inherent ability to synthesize and accumulate lipids to over 20% of their dry cell weight (DCW) are termed oleaginous.
    [Show full text]
  • Lecture 3 Mutagens and Mutagenesis A. Physical and Chemical
    Lecture 3 Mutagens and Mutagenesis 1. Mutagens A. Physical and Chemical mutagens B. Transposons and retrotransposons C. T-DNA 2. Mutagenesis A. Screen B. Selection C. Lethal mutations Read: 508-514 Figs: 14.23-28 1 Transposon (transposable element) as a mutagen Transposon (or TE): DNA segment that can move from one position to another (1) Retrotransposons Copia Drosophila (LTR-type) Ty1 Yeast (LTR-type) LINEs Human (non-LTR-type) SINEs (Alu) Human (non-LTR-type) (2) Transposons Ac/Ds Maize P-element Drosophila 2 Retrovirus Figure 5-73. The life cycle of a retrovirus. The retrovirus genome consists of an RNA molecule of about 8500 nucleotides; two such molecules are packaged into each viral particle. The enzyme reverse transcriptase first makes a DNA copy of the viral RNA molecule and then a second DNA strand, generating a double-stranded DNA copy of the RNA genome. The integration of this DNA double helix into the host chromosome is then catalyzed by a virus-encoded integrase enzyme. This integration is required for the synthesis of new viral RNA molecules by the host cell RNA polymerase, the enzyme that transcribes DNA into RNA. (From Molecular Biology of the Cell by Alberts et al.) 3 Fig. 14.26 4 5 Figure 5-76. Transpositional site- specific recombination by a nonretroviral retrotransposon. Transposition by the L1 element (red) begins when an endonuclease attached to the L1 reverse transcriptase and the L1 RNA (blue) makes a nick in the target DNA at the point at which insertion will occur. This cleavage releases a 3′-OH DNA end in the target DNA, which is then used as a primer for the reverse transcription step shown.
    [Show full text]
  • ADRIAMYCIN® Solution for Injection
    PRODUCT INFORMATION ADRIAMYCIN® Solution for Injection WARNINGS 1. For intravenous or intravesical use only. Severe local tissue necrosis will occur if there is extravasation during administration. ADRIAMYCIN must not be given by the intramuscular or subcutaneous route. 2. Serious irreversible myocardial toxicity with delayed congestive failure often unresponsive to any cardiac supportive therapy may be encountered as total dosage approaches 550 mg/m2. This toxicity may occur at lower cumulative doses in patients with prior mediastinal irradiation or on concurrent cyclophosphamide therapy. 3. Dosage should be reduced in patients with impaired hepatic function. 4. Severe myelosuppression may occur. 5. ADRIAMYCIN should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. NAME OF MEDICINE Non-proprietary name: doxorubicin hydrochloride The structural formula of doxorubicin hydrochloride is shown below: CAS Registry Number: 25316-40-9 Chemical name: (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]- 6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10- tetrahydrotetracene-5,12-dione hydrochloride Molecular formula: C27H29NO11,HCl Molecular weight: 580.0 Version: pfpadrii10612 Supersedes: pfpadrii10909 1 of 18 DESCRIPTION Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin hydrochloride is an orange-red, crystalline, hygroscopic powder that is soluble in water and slightly soluble in methanol. ADRIAMYCIN Injection is a red coloured, clear solution and should be stored at 2°C - 8°C. ADRIAMYCIN Injection is available in vials containing the active ingredient doxorubicin hydrochloride 10 mg/5 mL, 20 mg/10 mL, 50 mg/25 mL and 200 mg/100 mL.
    [Show full text]